• Description
  • Programmes
  • Contact

Sectors: Health, Innovation, Research, Social Affairs

Beneficiaries: Administrations States, Corporations, International Organisation, Research centres, SMEs, Universities

Regions: Balkans, Candidate countries, Developing countries, European Economic Area, European Union, Mediterranean countries, New Independant States, Switzerland

Category: Call for Proposals

References:

To view this information, please connect.

Linkedin:

WE funding – Horizon 2020 – Support…
Funds for: To support health innovative actions
Main beneficiaries: Corporations, SMEs, Research centres

Responsible: European Commission

Useful:

To view this information, please connect.

Amorce:

Funds for: To support health innovative actions
Main beneficiaries: Corporations, SMEs, Research centres

Priorities and funded actions:

Topics
Open
– IMI2-2018-16-01: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
– IMI2-2018-16-02: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
– IMI2-2018-16-03: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
– IMI2-2018-16-04: Determination of gepotidacin levels in tonsils and prostatic tissue
– IMI2-2018-16-05: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
– IMI2-2018-16-06: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
– IMI2-2018-16-07: Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)